A retrospective analysis reviewed 2285 patients with STS, calculated the necessary dose needed for each patient, and estimated the average waste associated with dispensing LARTRUVO 500 mg/50 mL vials. The average waste per patient per administration was approximately 234 mg. Using a combination of 190 mg/19 mL and 500 mg/50 mL vials, the average waste per patient per administration was reduced to 29 mg, an 87.6% reduction.1
Reference: 1. Data on file. Lilly USA, LLC. OLA20170210.
You are now leaving the www.LARTRUVO.com website.
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Please see full Prescribing Information for LARTRUVO.
OR HCP ISI 19OCT2016